Introduction
Aspirin is one of the safest and most useful of drugs. Its gastric effects are a problem in Great Britain, however, because of the large quantity of this drug that is consumed. A recent survey indicated that four and a half million people took aspirn at least once a week and that half a million took more than five asprin tablets a day. The risk to an individual of a serious aspirininduced gastric haemorrhage is very small, but when consumption of the drug by the community is so vast even a small risk becomes an important problem. In recognition of this the Committee on Safety of Drugs (1971) recently stressed that in its view preparations containing aspirin should not be recommended for the relief of stomach disorders, including gastric upsets and heartburn.
Probably one-quarter of all cases of haematemesis and melaena in Great Britain are precipitated by aspirin (Parry and Wood, 1967; Valman et al., 1968; Croft, 1970) . This represents about 7,000 admissions to hospital a year (Schiller et al., 1970) .
From other data it can be calculated that with continuous ingestion 1 g of aspirin a day causes about 1 ml of blood loss (Wood et al., 1962; Croft and Wood, 1967) . If this figure is applied to the whole community aspirin consumption can be said to be responsible for the gastrointestinal loss of more than 20,000 gallons (90,0001.) of blood a year-enough blood to fill a domestic swimming pool. This chronic blood loss can cause iron-deficiency anaemia, although the extent to which this is a community problem has not been defined.
It is important, therefore, to produce and study formulations of aspirin that may be less hafiul to the stomach. The "lCrlabelled red cell technique is the most accurate means of studying the gastric effect of aspirin, as it is possible by its use to measure blood losses as small as 1 0-2 0 ml/day. It has been shown with this technique that between 70 and 90% of patients taking aspirin continuously lose more than 2 ml/day (Scott et al., 1961; Wood et al., 1962; Croft and Wood, 1967) . Soluble aspirin causes as much bleeding as plain aspirin, and other preparations, such as choline salicylate (Cuddigan et al., 1971) , are no better. The simultaneous administration ofa large quantity of aLkali is associated with less bleeding, as is the use of entericcoated and delayed-release preparations.
Benorylate, 4-acetamidophenyl 2-acetoxybenzoate, is a new lipid-soluble ester of acetylsalicylic acid and N-acetyl p. aminophenol. It is an odourless, tasteless compound which is well absorbed from the gastrointestinal tract. Animal studies have shown that it has anti-inflammatory, analgesic, and antipyretic properties comparable with those of aspirin and that its activity is more prolonged (Rosner et al., 1971) . In addition, excellent gastrointestinal tolerance in both rats and dogs was noted. With the approval of the Dunlop Committee preliminary trials have been undertaken with benorylate in the treatment of rheumatoid ardtritis. Clinically the drug is reported to be as effective as aspirin as an antirheumatic drug (Sperryn et al., 1971; Beales et al., 1972) .
The present study was undertaken to compare occult gastrointestinal bleeding in patients taing benorylate with that in the same patients while taking soluble aspirin by a new and simplified clinical procedure that we have developed (Cuddigan et al., 1971 (Clapham and Hayter, 1962) , and the volume of blood in each stool was calculated. The details and validity of the technique have been published elsewhere (Cuddigan et al., 1971) .
Results
Five patients were excluded from the analysis because of incomplete stool collections, intercurrent illness, or failure to take the drugs. From the remaining 15 patients 121 stools were received. Previous work suggests that a mean daily blood loss of more than 2 ml/day should be regarded as clinically significant for this method (Croft and Wood, 1967; Cuddigan et al., 1971) . The mean daily blood loss with aspirin was 5-1 ml (S.D. 4.3) and with benorylate 1-7 ml (S.D. 1-6) (see Table) . The .P <0.001.
was statistically significant (P <0 001). Of these 15 patients, four showed no significant bleeding with either preparation. If these patients are excluded the mean daily blood loss with benorylate was 2-1 ml (S.D. 1-71), which was still significantly less than that with soluble aspirin (6-8 ml, S.D. 4-6; P <0001). In the 11 patients who bled, the amounts lost during aspirin and benorylate treatment are represented in the Chart. In nine of the 11 patients bleeding was more heavy and more frequent with aspirin. No with benorylate. Two patients' blood loss was almost equal with the two drugs. They were recalled and a further stool collection was made after all therapy had been withdrawn, no bleeding was detectable in either patient. We conclude therefore that in these two patients bleeding was caused by both aspirin and benorylate.
Discussion
The 61Cr-labelled red cell method is the most accurate way of measuring drug-induced gastric bleeding. We have simplified the procedure used by Scott et al. (1961) to produce a convenient outpatient procedure (Cuddigan et al., 1971) . As only eight stool specimens are collected and the patient has to attend hospital on only three occasions, rheumatological outpatients, who are at greater risk from salicylate therapy, can be readily studied. With the crossover procedure each patient acts as his own control and it is possible to compare the effects of a new drug with that of soluble aspirin. Any trial in which such a comparison is not made may give misleading results, since not all subjects are susceptible to aspirin-induced bleeding. We have found the method described above to be reliable.
The results of this study indicate that occult bleeding is an infrequent complication of benorylate therapy. The drug compares well in this respect with all salicylate preparations previously examined, and the mean blood loss of the 15 patients during benorylate therapy was within the normal range at 1-7 ml/day. Two patients did, however, show a definite increase in their blood loss during benorylate therapy. In the 11 patients who bled there was no correlation between the amounts of bleeding on aspirin and on benorylate (r = 0-50).
This study lends further support to the view that with regard to occult drug-induced gastric bleeding three groups of subjects can be distinguished (Croft and Wood, 1967) . Firstly, those who do not bleed and who make up some 10% of the population. Secondly, the majority (80%), who are sensitive to aspirin and lose 2-10 ml of blood/day. It is this group who do not bleed with benorylate, as is shown in the study. Finally there is a group (10%) who are particularly susceptible to gastric irritants and lose more than 10 ml/day when taking aspirin. One would expect that these subjects might also be susceptible to less irritant drugs such as benorylate. Thompson and Anderson (1970) , when studying Ibuprofen, which is generally believed to have little gastric effect, found some evidence of blood loss during treatment. At least two of their patients lost more than 2 ml daily, and in one the loss reached 6 ml; this was a patient who was also sensitive to aspirin. Thus even if a drug is shown to be substantially better than soluble aspirin in regard to bleeding, there will be some individuals who are susceptible to it.
One cannot draw direct conclusions about acute gastric haemorrhage from results obtained by measuring occult bleeding. However, it seems reasonable to believe that a drug that causes less occult bleeding than aspirin is also less likely to precipitate acute haemorrhage. Clearly other factors affect the susceptibility of the gastric mucosa to insults (British Medical Journal, 1970 ) and need to be elucidated by further research. 
